Tuberculosis Testing: TB Blood Tests and Screening

How Tuberculosis Spreads and Why Screening Matters

Tuberculosis is caused by a bacterium that spreads through the air when a person with active lung disease coughs, speaks, or sings. Not everyone who breathes in the bacteria becomes sick. Many people develop a latent infection, in which the bacteria stay quiet in the body and cause no symptoms. Screening matters because latent infection can later reactivate into active disease, especially when the immune system weakens.

Finding and treating latent infection is a core public health strategy. It protects the person from future illness and reduces the chance of spread to others. That is why testing is common in healthcare work, certain travel, and after close contact with someone who has active TB.

TB Blood Tests: How They Work

The interferon gamma release assay, often called an IGRA or TB blood test, measures how the immune system responds to proteins unique to the tuberculosis bacterium. A blood sample is mixed with these proteins in the laboratory. If the person has been infected, immune cells release interferon gamma, which the test detects.

An IGRA requires a single blood draw and a follow-up visit is not needed for reading. It is not affected by prior BCG vaccination, which makes it useful for people who were vaccinated in childhood. Results are usually reported as positive, negative, or indeterminate. An indeterminate result means the test could not give a clear answer and may need to be repeated.

The Tuberculin Skin Test

The tuberculin skin test, also called the Mantoux test, injects a small amount of purified protein under the skin of the forearm. A trained reader examines the site about two to three days later and measures any raised area. The size of the reaction is combined with the person's risk factors to decide whether the result is considered positive.

The skin test needs a return visit for reading, and the measurement must be done in person. Prior BCG vaccination can cause a false positive, which is one reason blood tests are often preferred when vaccination history is a concern. Neither the skin test nor the blood test can tell latent infection from active disease on its own.

Latent Infection Versus Active TB Disease

Latent tuberculosis infection means the bacteria are present but inactive. The person has no symptoms and cannot spread the infection to others. Active TB disease means the bacteria are multiplying and causing illness, often with a persistent cough, fever, night sweats, and weight loss. Active lung disease can be contagious.

The distinction is the reason a positive screening test is a starting point, not a diagnosis. A positive IGRA or skin test shows that the immune system has met the bacterium. Deciding whether that means latent infection or active disease requires a medical evaluation, which may include symptoms, imaging, and laboratory samples.

Reading a Positive TB Screening Result

A positive result means the test detected an immune response to tuberculosis proteins. It does not prove that a person is currently sick or contagious. Indeterminate results are common in people with weakened immune systems or in samples handled outside the expected conditions, and they call for a repeat test.

Reporting standards for the skin test also matter. A reaction that would be negative in a low-risk person may be read as positive in someone with a weakened immune system or recent close contact. The threshold shifts with risk, so the same measurement can carry different meaning for different people.

Chest Imaging and Sputum Testing

When a screening test is positive, the next step is to look for active disease. A chest X-ray can show changes in the lungs that suggest infection. If imaging or symptoms raise concern, laboratory testing of sputum follows. Sputum samples are examined for the bacteria using smear microscopy, culture, and nucleic acid tests that detect bacterial DNA.

Culture remains an important reference method because it can confirm live bacteria and allow drug-susceptibility testing, which guides treatment. Nucleic acid testing can return results faster than culture and help confirm active disease sooner. Together, imaging and laboratory testing separate latent infection from active, contagious disease.

Who Should Be Screened

Screening is recommended for people at higher risk, including close contacts of someone with infectious TB, healthcare workers, people who have lived or worked in high-prevalence settings, and those with conditions or medications that weaken the immune system. People planning to start certain biologic treatments may also be screened first, because latent infection can reactivate when immunity drops.

Routine screening is not needed for everyone. A provider can weigh risk factors and decide whether a blood test or skin test is appropriate. Screening programs often repeat testing at intervals for people with ongoing occupational exposure.

How to Prepare for TB Testing

TB blood tests need no fasting and usually require only a single blood draw. The main preparation is timing and honesty about your history. Tell the provider about past BCG vaccination, prior positive tests, and any immune-suppressing medications, because these affect which test is chosen and how results are read.

If you have a skin test scheduled, plan to return for the reading visit within the required window. Missing that visit wastes the test and means it must be repeated. Bring records of any previous TB tests so trends can be compared rather than treated as new findings.

When to Talk to a Provider

Talk to a provider if you have a cough lasting more than a few weeks, coughing up blood, fever, night sweats, or unexplained weight loss, or if you have had close contact with someone who has active TB. These signs need prompt evaluation to rule out active disease.

A provider can also explain what a positive screening means for your work, travel, or treatment plan and can arrange preventive therapy for latent infection when appropriate. This guide is educational information, not medical advice.